MedTrace Logo

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2022-02-21

Study results available
· View outcomes & findings →

Summary

A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.

Conditions

  • Asthma
  • Bronchial Diseases
  • Respiratory Tract Diseases
  • Lung Diseases, Obstructive
  • Lung Diseases
  • Respiratory Hypersensitivity
  • Hypersensitivity, Immediate
  • Hypersensitivity
  • Immune System Diseases

Interventions

BIOLOGICAL

Tezepelumab

Tezepelumab subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Chris Brightling · University of Leicester, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-02
Primary Completion
2020-11-16
Completion
2020-11-16
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Denmark
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688074 on ClinicalTrials.gov